{"id":3970,"date":"2020-02-12T16:44:06","date_gmt":"2020-02-12T15:44:06","guid":{"rendered":"https:\/\/idibell.cat\/en\/?page_id=3970"},"modified":"2025-05-21T17:19:26","modified_gmt":"2025-05-21T15:19:26","slug":"pluripotent-stem-cell-therapy","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/regenerative-medicine-area\/regenerative-medicine-program\/pluripotent-stem-cell-therapy\/","title":{"rendered":"Pluripotent Stem Cell Therapy"},"content":{"rendered":"\n

\n\t\tPluripotent stem cell therapy\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\tThe goal of the group is to develop and improve the methodologies for the generation and differentiation of pluripotent stem cells (PSC), both human embryonic stem cells (hESC) and human induced pluripotent stem cells (hiPSC) for their clinical application in cell therapy.
\nThe group is working on the generation and banking of iPSC lines under clinically safe conditions derived from cord blood samples from homozygous haplotypes to establish a collection of iPSC lines compatible with a significant percentage of the Spanish population. The generation methodology is under xeno-free and defined conditions, towards Good Manuphacturing Practices (GMP).
\nIn a collaboration of the Banc de Sang i Teixits (BST) and the Banc de l\u00ednies cel\u00b7lulars de Barcelona (BLC-B) a project titled: Allogenic hIPSC from homozygous UCB units for high prevalence haplotypes (iPS-PANIA) is carried out.
\nThe main goal is the development of a Stem Cell Bank of allogenic hiPSCs with pharmaceutical grade quality generated from cord blood units homozygous for frequent haplotypes to provide useful cell lines for basic research and clinical trials oriented to cell therapy .
\nSpecific intermediate objectives:
\ni. Ethical review of the new contact with the donors and the new therapeutic uses of the donated cells.
\nii. Creation, characterization and validation of a registry of Umbilical cord blood units (CBU) with the HLA most represented in the population of our geographical area.
\niii. Definition of the criteria, selection and contact with 7 donors with prevalent HLA.
\niv. Reprogramming of 7 CBU: creation of the active principle.
\nv. Expansion of 7 iPSC lines under GMP conditions: creation and registration of the Master Cell Bank.
\nvi. Expansion of 7 iPSC lines under GMP conditions: creation of the Working Cell Bank and offer to conduct clinical trials.
\nThis project will be carried out, through the progressive implementation of consistent activities with these objectives, by 2 organizations: the Banc de Sang i Teixits (with the subcontracting of the PNSCU banks for the transfer of homozygote haplotype sample and ethical and legal review of the processes), and the Regenerative Medicine Programme( PCMR-C), that, as a whole, possess the knowledge, technical and structural resources necessary to carry it out.\n

214<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"Pluripotent-Stem-Cell-Therapy\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Allogeneic hiPSC generation from cord blood units with frequent\u00a0HLA homozygous haplotypes.<\/p>\n

Cell therapy with hiPSC-derived retinal pigment epithelium and photoreceptor progenitors in a swine model of geographic atrophy.<\/p>\n

Genome editing with CRISPR\/Cas9 in human embryos for the study of early embryonic development.<\/p>\n

\u00a0<\/p>\n\t\t\t\t\tSelected Publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t